Development of pk/pd Model of Propofol in Patients With Severe Burns (HUAPQ)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03704285|
Recruitment Status : Recruiting
First Posted : October 12, 2018
Last Update Posted : February 28, 2019
Burn injuries are a prevalent problem. Actually, in Chile the Ministry of Health has recorded 6435 hospital burns and has reported 569 deaths from this cause. The specific mortality rate for burning in Chile was 4.5 per 100,000 inhabitants per year. Survival in extensive burns has progressively improved, thanks to advances in understanding the pathophysiology of the burn and its more aggressive treatment. This requires effective prehospital treatment, transportation, resuscitation, support of vital functions and repair of the skin cover.
Much of the procedures performed in large burns require general anesthesia. Being Total Intravenous Anesthesia (TIVA) with propofol an alternative that would have advantages over inhalational anesthesia, as a decrease in postoperative nausea and vomiting and produce less environmental pollution 3 and the antihyperalgesic effect of propofol. Within TIVA - Target Control Infusion (TCI) - uses infusion systems that incorporate PK-PD models for predict the dose of drug required to reach a certain concentration in the target organ.
The formulation of a PK model that considers the variables of this group of patients, such as: degree of injury, inflammatory state and compromised body surface; associated with general variables such as: age, weight and nutrition, it would allow to reduce the predictive error in this population, thus improving the dosing of these patients when using TCI.
Given the lack evidence on the PK-PD of propofol is this group of patients burned, has led to raise the development of this study that seeks to develop a PK-PD model that fits them.
|Condition or disease||Intervention/treatment|
|Anesthesia Burned Operative Wound||Drug: Propofol Device: BIS|
Patients will be invited to participate before surgery, the inclusion criteria will be revised and the informed consent will be signed.
In the operating room will be recorded demographic data and relevant background such as: Age, Weight, Size, BMI, Lean Mass, Fat Mass and Total body water among others.
Afterwards, in the operating room, the patient will be monitored regularly: ECG (DII) if feasible and pulse oximetry. An arterial catheter will be installed for monitoring and taking blood samples during the intraoperative period.
In addition, the EEG will be monitored through a frontal electroencephalographic monitoring (BIS) system; that will be recorded throughout the surgery.
The anesthetic induction will be with propofol and remifentanil. The propofol will be administered using an initial bolus of 1-2 mg / kg according to the criteria of the anesthetist and then a continuous infusion of 10 mg / kg / hr that will be adjusted adjusted to maintain a BIS between 40 and 60.
Plasma samples of propofol: arterial samples of 3-4 ml will be taken at 2, 5, 10, 30, 60 and/or 120 min after beginning the administration of propofol. Subsequently samples will be taken at 0, 5, 15, 30, 60, 120, 240 min and at 6-12 hrs after stopping the infusion of propofol. The samples will be centrifuged and stored at -20 ° C until analysis by HPLC.
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Development of Pharmacokinetic / Pharmacodynamic (pk/pd) Model of Propofol in Patients With Severe Burns|
|Actual Study Start Date :||September 29, 2018|
|Estimated Primary Completion Date :||October 30, 2019|
|Estimated Study Completion Date :||December 30, 2019|
Severe burn adult under general anesthesia with propofol + remifentanil evaluation of propofol effect using BIS
Patients undergoing general anesthesia using target controlled infusion of propofol. Initial bolus of 1-2 mg/kg and then a continuous infusion of 10 mg/kg/hr that will be adjusted adjusted to maintain a BIS between 40 and 60.
Other Name: Propofol Intravenous dose
GeneralAnesthesia maintenance with propofol+remifentanil guided by BIS monitoring.
Other Name: General anesthetic
- Propofol plasmatic levels Measured by high pressure liquid chromatography [ Time Frame: From start of propofol infusion to 12 hrs after stopped infusion of propofol. ]Propofol total dose. 2, 5, 10, 30, 60 and 120 min after induction with propofol. Subsequently, samples will be taken at 0, 5, 15, 30, 60, 120, 240 min and at 6-12 hrs after stopping infusion of propofol.
- Hemodynamics [ Time Frame: Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs. ]Arterial pressure (mmHg)
- Heart Rate [ Time Frame: Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs. ]Heart rate (bpm)
- Pulse oximetry [ Time Frame: Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs. ]% oximetry saturation
- BIS [ Time Frame: Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs. ]Depth of anesthesia will be recorded with BIS monitor. From 60 - 40
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03704285
|Contact: VICTOR E CONTRERAS, MSNfirstname.lastname@example.org|
|Contact: Marcela A Avila, MDemail@example.com|
|Santiago, Región Metropolitana, Chile, 8420525|
|Contact: VICTOR CONTRERAS, MSN 56223549217 firstname.lastname@example.org|
|Contact: Marcela Avila, MD 56988376943 email@example.com|
|Sub-Investigator: Luis I Cortinez, MD|
|Principal Investigator: Marcela A Avila, MD|
|Study Director:||Luis I Cortinez, MD||Pontificia Universidad Catolica de Chile|